How does vaxcyte, inc. make money?

vaxcyte, inc. generates $20M in annual revenue (annual revenue).

What is PCVX's XVARY composite score?

vaxcyte, inc. (PCVX) has an XVARY composite score of 36/100, rated weak. This combines growth, value, risk, and momentum factors.

PCVX — vaxcyte, inc. stock analysis

Start here if you're new

what it is

Vaxcyte builds vaccine candidates for infections with a lab-made protein system, not a commercial factory.

how it gets paid

Last year Vaxcyte made $20M in revenue.

what just happened

Vaxcyte missed by 25.9% after a $1.80 loss versus a $1.43 loss estimate.

At a glance

B+ balance sheet — decent shape, but not bulletproof

45/100 earnings predictability — expect surprises

51.0% return on capital — a money-printing machine

xvary composite: 36/100 — weak

-$6.50 fy2027 eps est

What they do

Vaxcyte builds vaccine candidates for infections with a lab-made protein system, not a commercial factory.

Vaxcyte has 414 employees and a cell-free protein synthesis platform. cell-free protein synthesis platform → lab-made protein engine → the company can design vaccine parts without living cells. That matters because the business is still preclinical, so control and speed are the only edge you can measure today.

biotech clinical-stage small-cap vaccines pre-revenue

How they make money

$20M annual revenue

total revenue

$20M

n/a

The products that matter

lead vaccine pipeline

pneumococcal vaccine program

targets a $6B franchise

This is the program carrying most of the narrative weight. If it can take share from Pfizer's $6B Prevnar franchise, the $7B valuation looks less aggressive. If not, the math gets uncomfortable fast.

core thesis

vaccine platform technology

optimized protein carriers

science before sales

These engineered carriers are the enabling technology behind the pipeline. With only $20M in current revenue, you are still underwriting platform credibility rather than commercial proof.

platform bet

antigen design stack

antigens and vaccine building blocks

no standalone monetization yet

These building blocks matter because they shape the shots Vaxcyte hopes to sell later. Today, though, they are inputs to a thesis, not products you can value on their own.

pipeline inputs

Key numbers

$7B

market cap

You are paying $7B for a company with $0 commercial revenue. That is a long wait for proof.

$25M

FY2027 sales

The base case is tiny. $25M on a $7B market cap is 280x sales.

-$6.50

FY2027 EPS

That is a deep loss. The company is expected to burn through profit, not make it.

$77

target price

That is 42% above $54.10. Wall Street still sees upside, but only if the pipeline works.

Financial health

B+

strength

balance sheet grade B+ — solid but not elite
risk rank 4 — safer than 20% of stocks
price stability 10 / 100
net profit margin 20.0% — keeps 20 cents of every dollar in revenue
return on equity 51% — $0.51 profit for every $1 investors have put in

B+ — functional but not a standout on the balance sheet.

Total return vs. market

You invested $10,000 in PCVX 3 years ago → it's now worth $12,570.

The index would have given you $13,880.

same period. same starting point. PCVX trailed the market by $1,310.

source: institutional data · total return

What just happened

missed estimates

Vaxcyte missed by 25.9% after a $1.80 loss versus a $1.43 loss estimate.

No commercial products meant no revenue. That left R&D spending as the whole story.

$0M

revenue

-$1.80

eps

n/a

eps miss

The $1.80 loss mattered because it was 25.9% worse than the $1.43 estimate.

vaxcyte shares continued to gain investor support over the past three months.
at the recent quotation, pcvx shares have increased over 10% in value.
still, the equity remains well below its 52-week high.

the wide trading range suggests the stock may have a penchant for volatility, and is thus not suited for the faint of heart. at first glance, the buying may seem surprising since the company intends to release 2025 results after this issue was published. however, given the lack of commercial status, investors may be increasing their positions in risky pcvx shares due to untapped potential. the company recently augmented its balance sheet by $632.5 million, through a public share offering.
vaxcyte released 12,650,000 shares to the public, at a price offering of $50.00 per share.

the financial shot in the arm will likely be used to fund crucial pipeline endeavors already underway.
vax-31 is arguably the most promising pipeline candidate.

source: company earnings report, 2026

What could go wrong

The risk picture is company-specific and pretty clear: the lead pneumococcal program can disappoint, financing can dilute you, and a stock priced on future approval can re-rate fast when sentiment breaks.

∘

med

pipeline failure hits almost the whole thesis

PCVX has no approved products and just $20M in revenue. Most of the $7B valuation rests on the idea that its vaccine pipeline, especially in pneumococcal disease, becomes commercially real.

If key programs stumble, there is very little current business to support the stock on fundamentals.

∘

med

dilution risk is not theoretical

Recent public discussion centered on a heavy equity raise and a $766.63M full-year 2025 net loss. That is the classic biotech funding loop.

If development keeps consuming capital faster than expected, new shares can absorb future upside before shareholders do.

∘

med

expectations can break even on good news

The stock dropped on positive data on Mar 31, 2025, and price stability is just 10 / 100. That is your reminder that sentiment matters almost as much as results here.

You can be directionally right on the science and still lose money if the market had already priced in better.

At ~$7B against $20M in revenue and no approved products, almost the entire valuation is exposed to pipeline execution and financing discipline.

source: institutional data · regulatory filings · risk analysis

Pay attention to

calendar

next earnings report

For this company, the cash burn language matters as much as the pipeline update. Listen for runway, financing plans, and what management says about commercialization timing.

valuation gap

$20M revenue versus a ~$7B market cap

That contrast is the whole story. Until approved products exist, you are underwriting future outcomes more than current operations.

ownership trend

institutional flow is involved, not enthusiastic

135 buyers versus 145 sellers in 3Q2025 tells you the stock still has sponsorship, but the big money is not all leaning the same way.

risk

losses and financing can outrun the science

FY2027 EPS is still estimated at -$6.50. If capital needs stay elevated, shareholders can win on data and still get diluted on the path there.

Analyst rankings

earnings predictability

45 / 100

Earnings are hard to model here because the business is not mature. In human-speak, analysts do not have a clean operating template to lean on.

price stability

10 / 100

This stock is volatile even by growth-stock standards. Trial headlines, financing headlines, and sentiment all move the tape.

balance sheet quality

B+

The balance sheet is serviceable for a development-stage biotech. That helps, but it does not erase execution risk.

source: institutional data

Institutional activity

135 buyers vs. 145 sellers in 3q2025. total institutional holdings: 0.1B shares.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$40 $113

$54 current price

$77 target midpoint · +42% from current · 3-5yr high: $75 (+40% · 9% ann'l return)

source: institutional data · analyst targets

The deep dive

PCVX

xvary deep dive

pcvx

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

pcvx

Get this snapshot in your inbox

Want the deeper analysis?